Gyre Therapeutics Cash Flow Statement (2010-2026) | GYRE

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Operating Activities
Net Income (Quarter)	-27.71M	-20.99M	-14.54M	51.63M	-4.88M	-28.79M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	0.16M	-9.86M	-14.27M
Depreciation and Depletion (Quarter)																0.80M				1.10M
Share-based Compensation (Quarter)																				1.83M
Deferred Taxes (Quarter)																				-1.43M
Gains from Investment Securities (Quarter)											-4.29M	-2.91M	0.23M	-0.19M	-2.25M	-0.21M	0.02M	-0.26M	-0.09M
Asset Writedowns and Impairment (Quarter)			0.20M
Cash from Operations (Quarter)																				-16.75M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
Depreciation & Amortization (CF) (Quarter)																				1.48M
Change in Working Capital
Change in Receivables (Quarter)																				4.47M
Change in Inventory (Quarter)																				-0.09M
Change in Account Payables (Quarter)																				4.66M
Change in Accured Expenses (Quarter)																				-0.50M
Change in Taxes (Quarter)																				-1.02M
Other Working Capital Changes (Quarter)																				-2.98M
Investing Activities
Capital Expenditures (Quarter)																				0.26M
Sales of Property, Plant and Equipment (Quarter)																				0.01M
Change in Intangibles (Quarter)							1.00M
Change in Acquisitions & Divestments (Quarter)																				3.00M
Cash from Investing Activities (Quarter)																				9.76M
Financing Activities
Other financing activities (Quarter)																				0.20M
Cash from Financing Activities (Quarter)																				-0.01M
Change in Capital Stock
Net Equity Issued and Repurchased (Quarter)															0.51M	23.00M	1.28M	-23.51M	0.50M
Dividend Payments
Dividends Paid - Common (Quarter)							7.76M	3.50M	1.50M
Additional items
Exchange Rate Effect (Quarter)																				0.64M
Change in Cash (Quarter)																				-6.34M
Free Cash Flow (Quarter)																				-17.01M
Net Cash Flow (Quarter)																				-7.00M

Research Tools

Datasets

Plans

Developers

Gyre Therapeutics Cash Flow Statement (2010-2026) | GYRE

Research Tools

Datasets

Plans

Developers

Gyre Therapeutics Cash Flow Statement (2010-2026) | GYRE

Create an account

Sign In

Reset Password